Cingulate Inc. (CING): Total Liabilities
$12.56M
As of 2025-12-31
$9.60M
As of 2026-06-30
+18.6%
3-year compound annual growth
+22.8%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $12.56M | +69.6% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $7.41M | -28.5% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $10.36M | +37.7% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $7.52M | +268.3% | 2024-04-01, Balance as of period end |
| 2021-12-31 | $2.04M | -54.6% | 2023-03-10, Balance as of period end |
| 2020-12-31 | $4.50M | n/a | 2022-03-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Cingulate Inc. (CING) | 2025-12-31 | $12.56M | +69.6% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $5.06M | -48.4% |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $7.28M | -50.5% |
| Biovie Inc. (BIVI) | 2026-06-30 | $3.98M | +56.1% |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $2.13M | -21.2% |
| Exicure, Inc. (XCUR) | 2025-12-31 | $10.12M | +22.1% |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $6.11M | -33.7% |
| CytoDyn Inc. (CYDY) | 2026-05-31 | $123.69M | +8.4% |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $1.48M | -56.9% |
Compare CING, CLRB, RVPH, BIVI side by side · Screen every company in Pharmaceutical Preparations ↗